Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Shares Outstanding (Diluted Average): 2009-2024

Historic Shares Outstanding (Diluted Average) for Ani Pharmaceuticals (ANIP) over the last 16 years, with Dec 2024 value amounting to $19.3 million.

  • Ani Pharmaceuticals' Shares Outstanding (Diluted Average) rose 8.70% to $21.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.1 million, marking a year-over-year increase of 8.70%. This contributed to the annual value of $19.3 million for FY2024, which is 6.18% up from last year.
  • Per Ani Pharmaceuticals' latest filing, its Shares Outstanding (Diluted Average) stood at $19.3 million for FY2024, which was up 6.18% from $18.2 million recorded in FY2023.
  • Over the past 5 years, Ani Pharmaceuticals' Shares Outstanding (Diluted Average) peaked at $19.3 million during FY2024, and registered a low of $12.0 million during FY2020.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $17.9 million, with a median of $18.2 million in 2023.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Shares Outstanding (Diluted Average) declined by 0.63% in 2020, and later grew by 29.09% in 2022.
  • Ani Pharmaceuticals' Shares Outstanding (Diluted Average) (Yearly) stood at $12.0 million in 2020, then increased by 5.28% to $12.6 million in 2021, then increased by 29.09% to $16.3 million in 2022, then rose by 11.89% to $18.2 million in 2023, then grew by 6.18% to $19.3 million in 2024.